Activity Overview
This online, on-demand virtual symposium brings together renowned experts in acute lymphoblastic leukemia (ALL). In this educational program, these experts discuss practical guidance on integrating T-cell therapies into clinical care, including challenges in treatment selection, sequencing, and toxicity management.
This educational activity is an archive of the live symposium held on February 26, 2026.
Target Audience
This activity is designed for hematologists, oncologists, transplant physicians, and advanced practice providers involved in the diagnosis and management of patients with ALL. Pharmacists, nurses, and other health care professionals engaged in the multidisciplinary care of patients receiving CAR T-cell therapy or bispecific antibody treatment will also benefit from this session.
Learning Objectives
Upon participation in this activity, learners will be better able to:
- Evaluate recent clinical trial data on approved and emerging therapeutic strategies for ALL, with a focus on advances in bispecific antibodies and CAR T-cell therapies
- Interpret the latest guidelines and evidence for biomarker-driven strategies to stratify risk and guide the use of bispecific and CAR T-cell therapies in patients with ALL
- Describe best practices for mitigating and managing treatment-related adverse events in patients with ALL
Elias Jabbour, MD
Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Dr. Jabbour has no relevant financial relationships with ineligible companies.
Hagop M. Kantarjian, MD
Professor, Department of Leukemia
Samsung Distinguished Leukemia Chair in Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, Ascentage, Ipsen, Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen TargetRx, Stemline, Takeda; Grant/Research Funding: AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Daiichi Sankyo, Immunogen, Novartis
Aaron C. Logan, MD, PhD, MPhil
Professor of Clinical Medicine
Director, Hematologic Malignancies Tissue Bank
Hematology, Blood & Marrow Transplant, and Cellular Therapy
Program
University of California, San Francisco
San Francisco, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Adaptive Biotechnologies, Amgen, Cabaletta Bio, Novartis, Orca, Pfizer, Sanofi, Servier, Takeda; Grant/Research Funding: Amgen, Astellas, Autolus, Gilead, Sanofi
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
